Literature DB >> 29195673

Alcohol, smoking and the liver disease patient.

Hannes Hagström1.   

Abstract

Alcohol is an established risk factor for cirrhosis. Current recommendations for a "safe" limit for alcohol consumption are usually set to around 30 g of alcohol per day for men and 20 g per day for women, but evidence is mounting that these cut-offs might be set too high. Also, inter-individual differences in the hepatic sensitivity for alcohol likely play into the risk of development of cirrhosis. In patients with concomitant liver diseases, a synergistic effect on fibrosis progression and high consumption of alcohol is evident. The role of low to moderate consumption is less clear. Alcohol can also lead to a specific inflammatory state in the liver, alcoholic hepatitis (AH). Treatment of severe AH consists of corticosteroids, which are at best moderately effective, and new treatments are needed. Liver transplantation is an option in severe alcoholic liver disease, although selection of patients that are at a very low risk of post-transplantation alcohol consumption is paramount. There is some evidence to suggest an increased risk for fibrosis progression and development of hepatocellular carcinoma specifically for smoking.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alcohol; Cirrhosis; Fibrosis; Liver disease; Smoking

Mesh:

Year:  2017        PMID: 29195673     DOI: 10.1016/j.bpg.2017.09.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  6 in total

Review 1.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

2.  Association between liver cirrhosis and peri-implant diseases: a case-control study on implant- and patient-related risk factors.

Authors:  Fernando Oliveira Costa; Sheila Cavalca Cortelli; José Roberto Cortelli; Eugênio José Pereira Lages; Gustavo Henrique Mattos Pereira; Adriana Moreira Costa; Luís Otávio Miranda Cota
Journal:  Clin Oral Investig       Date:  2021-12-02       Impact factor: 3.573

Review 3.  Research Progress on the Pharmacological Action of Schisantherin A.

Authors:  Zehao Xiao; Wen Xiao; Guilin Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-12       Impact factor: 2.629

4.  Association between serum ferritin, incident primary liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: A nested case-control study.

Authors:  Zhikai Zhu; Jian Yin; Sanford M Dawsey; Bin Liu; Neal D Freedman; Liangyu Yin; Philip R Taylor; Jianfeng Cui; Jinhu Fan; Yuanli Liu; Wen Chen; Youlin Qiao; Christian C Abnet
Journal:  J Gastroenterol Hepatol       Date:  2021-06-17       Impact factor: 4.369

Review 5.  Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma.

Authors:  Ramesh P Thylur; Sanjit K Roy; Anju Shrivastava; Thomas A LaVeist; Sharmila Shankar; Rakesh K Srivastava
Journal:  JGH Open       Date:  2020-04-15

Review 6.  Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts.

Authors:  Ralf Weiskirchen; Sabine Weiskirchen; Frank Tacke
Journal:  F1000Res       Date:  2018-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.